Harrigan JA, Jacq X, Martin NM, Jackson SP (2018) Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov 17(1):57–78

Article  CAS  PubMed  Google Scholar 

Clague MJ, Urbe S, Komander D (2019) Breaking the chains: deubiquitylating enzyme specificity begets function. Nat Rev Mol Cell Biol 20(6):338–352

Article  CAS  PubMed  Google Scholar 

Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell 123(5):773–786

Article  CAS  PubMed  Google Scholar 

Komander D, Clague MJ, Urbe S (2009) Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 10(8):550–563

Article  CAS  PubMed  Google Scholar 

Hu M, Li P, Li M, Li W, Yao T, Wu JW, Gu W, Cohen RE, Shi Y (2002) Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 111(7):1041–1054

Article  CAS  PubMed  Google Scholar 

Cunningham CN, Baughman JM, Phu L, Tea JS, Yu C, Coons M, Kirkpatrick DS, Bingol B, Corn JE (2015) USP30 and parkin homeostatically regulate atypical ubiquitin chains on mitochondria. Nat Cell Biol 17(2):160–169

Article  CAS  PubMed  Google Scholar 

Ordureau A, Sarraf SA, Duda DM, Heo JM, Jedrychowski MP, Sviderskiy VO, Olszewski JL, Koerber JT, Xie T, Beausoleil SA, Wells JA, Gygi SP, Schulman BA, Harper JW (2014) Quantitative proteomics reveal a feedforward mechanism for mitochondrial PARKIN translocation and ubiquitin chain synthesis. Mol Cell 56(3):360–375

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kubli DA, Gustafsson ÅB (2012) Mitochondria and mitophagy: the Yin and Yang of cell death control. Circ Res 111(9):1208–1221

Article  CAS  PubMed  PubMed Central  Google Scholar 

Narendra D, Walker JE, Youle R (2012) Mitochondrial quality control mediated by PINK1 and parkin: links to parkinsonism. Cold Spring Harb Perspect Biol 4:11

Article  Google Scholar 

Fang TSZ, Sun Y, Pearce AC, Eleuteri S, Kemp M, Luckhurst CA, Williams R, Mills R, Almond S, Burzynski L, Márkus NM, Lelliott CJ, Karp NA, Adams DJ, Jackson SP, Zhao JF, Ganley IG, Thompson PW, Balmus G (2023) Simon D. K. Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease mouse model. Nat Commun 14(7295)

Tsubouchi K, Araya J, Kuwano K (2018) PINK1-PARK2-mediated mitophagy in COPD and IPF pathogeneses. Inflamm Regen 38:18

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siekacz K, Piotrowski WJ, Iwański MA, Górski P, Białas AJ (2021) The role of interaction between mitochondria and the extracellular matrix in the development of idiopathic pulmonary fibrosis. Oxid Med Cel Longev 18:9932442–9932512

Article  Google Scholar 

Bingol B, Tea JS, Phu L, Reichelt M, Bakalarski CE, Song Q, Foreman O, Kirkpatrick DS, Sheng M (2014) The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature 510(7505):370–375

Article  CAS  PubMed  Google Scholar 

Marcassa E, Kallinos A, Jardine J, Rusilowicz-Jones EV, Martinez A, Kuehl S, Islinger M, Clague MJ, Urbe S (2018) Dual role of USP30 in controlling basal pexophagy and mitophagy. EMBO Rep 19:7

Article  Google Scholar 

Chen S, Liu Y, Zhou H (2021) Advances in the development Ubiquitin-Specific peptidase (USP) inhibitors. Int J Mol Sci 22:9

CAS  Google Scholar 

https://patentimages.storage.googleapis.com/f7/1a/37/2987b3e35e41d3/WO2021050992A1.pdf

https://vincerebio.com/news-data/Vincere-ADPD-2022.pdf

Mission Therapeutics Nominates First Development Candidates Targeting USP30 https://missiontherapeutics.com/mission-therapeutics-nominates-first-development-candidates-targeting-usp30/

Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in acute kidney injury. 14th December 2023 in Press Release. https://missiontherapeutics.com/mission-therapeutics-announces-us-fda-approval-to-initiate-phase-ii-clinical-trial-of-its-lead-asset-mtx652-in-acute-kidney-injury/

Mission Therapeutics commences Landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s disease. 21st March 2024 in Press Release. https://missiontherapeutics.com/mission-therapeutics-commences-landmark-trial-of-mtx325-a-potential-disease-modifying-treatment-for-parkinsons-disease/

Rusilowicz-Jones EV, Barone FG, Lopes FM, Stephen E, Mortiboys H, Urbé S, Clague MJ (2021) Benchmarking a highly selective USP30 inhibitor for enhancement of mitophagy and pexophagy. Life Sci Alliance 5(2):e202101287

Phu L, Rose CM, Tea JS, Wall CE, Verschueren E, Cheung TK, Kirkpatrick DS, Bingol B (2020) Dynamic regulation of mitochondrial import by the ubiquitin system. Mol Cell 77:1107–1123e10

Article  CAS  PubMed  Google Scholar 

Tsefou E, Walker AS, Clark EH, Hicks AR, Luft C, Takeda K, Watanabe T, Ramazio B, Staddon JM, Briston T et al (2021) Investigation of USP30 inhibition to enhance parkin-mediated mitophagy: tools and approaches. Biochem J BCJ20210508

Gersch M, Gladkova C, Schubert AF, Michel MA, Maslen S, Komander D (2017) Mechanism and regulation of the Lys6-selective deubiquitinase USP30. Nat Struct Mol Biol 24(11):920–930

Schrödinger (2022) Release 2022-3: Schrödinger, L., New York, NY

Halgren TA (2009) Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 49(2):377–389

Article  CAS  PubMed  Google Scholar 

https://patents.google.com/patent/WO2017103614A1/en?oq=WO2017103614A1

McPhillips TM, McPhillips SE, Chiu HJ, Cohen AE, Deacon AM, Ellis PJ, Garman E, Gonzalez A, Sauter NK, Phizackerley RP, Soltis SM, Kuhn P (2002) Blu-Ice and the distributed control system: software for data acquisition and instrument control at macromolecular crystallography beamlines. J Synchrotron Radiat 9(Pt 6):401–406

Article  CAS  PubMed  Google Scholar 

Kabsch W (2010) Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr D Biol Crystallogr 66(Pt 2):133–144

Article  CAS  PubMed  PubMed Central  Google Scholar 

McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ (2007) Phaser crystallographic software. J Appl Crystallogr 40(Pt 4):658–674

Article  CAS  PubMed  PubMed Central  Google Scholar 

Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66(Pt 4):486–501

Article  CAS  PubMed  PubMed Central  Google Scholar 

Afonine PV, Grosse-Kunstleve RW, Echols N, Headd JJ, Moriarty NW, Mustyakimov M, Terwilliger TC, Urzhumtsev A, Zwart PH, Adams PD (2012) Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr D Biol Crystallogr 68(Pt 4):352–367

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gavory G, O’Dowd CR, Helm MD, Flasz J, Arkoudis E, Dossang A, Hughes C, Cassidy E, McClelland K, Odrzywol E, Page N, Barker O, Miel H, Harrison T (2018) Discovery and characterization of highly potent and selective allosteric USP7 inhibitors. Nat Chem Biol 14(2):118–125

Article  CAS  PubMed  Google Scholar 

Wang Y, Jiang Y, Ding S, Li J, Song N, Ren Y, Hong D, Wu C, Li B, Wang F, He W, Wang J, Mei Z (2018) Small molecule inhibitors reveal allosteric regulation of USP14 via steric Blockade. Cell Res 28(12):1186–1194

Article  CAS  PubMed  PubMed Central  Google Scholar 

Faesen AC, Luna-Vargas MP, Geurink PP, Clerici M, Merkx R, Van Dijk WJ, Hameed DS, El Oualid F, Ovaa H, Sixma TK (2011) The differential modulation of USP activity by internal regulatory domains, interactors and eight ubiquitin chain types. Chem Biol 18(12):1550–1561

Article  CAS  PubMed  Google Scholar 

Mevissen TET, Komander D (2017) Mechanisms of deubiquitinase specificity and regulation. Annu Rev Biochem 86:159–192

Article  CAS  PubMed  Google Scholar 

O’Brien DP, Jones HBL, Guenther F, Murphy EJ, England KS, Vendrell I, Anderson M, Brennan PE, Davis JB, Pinto-Fernández A, Turnbull AP, Kessler BM (2023) Structural premise of selective deubiquitinase USP30 Inhibition by Small-Molecule benzosulfonamides. Mol Cell Proteom 22(8):100609

Article  Google Scholar 

O’Brien DP, Jones HBL, Shi Y, Guenther F, Vendrell I, Viner R, Brennan PE, Mead E, Zarganes-Tzitzikas T, Davis JB, Pinto-Fernández A, England KS, Murphy EJ, Turnbull AP, Kessler BM (2025) Structural dynamics of the ubiquitin specific protease USP30 in complex with a Cyanopyrrolidine-Containing covalent inhibitor. J Proteome Res 24(2):479–490

Article  PubMed  PubMed Central  Google Scholar 

Schauer NJ, Magin RS, Liu X, Doherty LM, Buhrlage S (2020) J. Advances in discovering deubiquitinating enzyme (DUB) inhibitors. J Med Chem 63(6):2731–2750